TScan Therapeutics will host a virtual KOL event on December 10 to discuss Phase 1 trial data and development strategies.
Quiver AI Summary
TScan Therapeutics, Inc., a biotechnology company focused on T cell receptor-engineered therapies for cancer treatment, has announced a virtual key opinion leader event set for December 10, 2024. The event will discuss findings from the ALLOHA Phase 1 trial for TCR-T therapies in patients with acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation. Attendees will receive updates on clinical development strategies and insights from an initial FDA meeting regarding the program's potential registrational path. The event will feature speakers from TScan, including CEO Gavin MacBeath and CMO Chrystal U. Louis. A replay will be available on the company’s investor relations website after the event.
Potential Positives
- TScan Therapeutics is hosting a virtual key opinion leader (KOL) event to present significant data from the ALLOHA Phase 1 heme trial, which indicates ongoing commitment to transparency and stakeholder engagement.
- The event will likely provide insights into a potential registrational path for their TCR-T therapy, which could enhance the Company's prospects for future product approval and market entry.
- Updates on the PLEXI-T Phase 1 solid tumor trial will be shared, showcasing the Company's active development pipeline and efforts to address multiple cancer types.
Potential Negatives
- The press release focuses on upcoming events and updates, which may indicate a lack of significant recent progress or results in ongoing trials, potentially raising concerns about the company’s current development trajectory.
- There is no mention of successful trial results or positive regulatory feedback, which could create doubt about the efficacy and viability of their therapies in a competitive market.
- The event is centered around preliminary results, which may suggest that the company is still far from achieving definitive outcomes necessary for market approval, particularly in a challenging regulatory environment.
FAQ
What is TScan Therapeutics announcing in their press release?
TScan Therapeutics is hosting a virtual KOL event to discuss data from their ALLOHA Phase 1 heme trial.
When will the virtual event take place?
The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET.
What topics will be covered during the event?
The event will cover preliminary results from the ALLOHA Phase 1 heme trial and updates on the PLEXI-T Phase 1 solid tumor trial.
Who are the featured speakers for this event?
Featured speakers include Ran Reshef, Gavin MacBeath, Chrystal U. Louis, and Shrikanta Chattopadhyay.
How can I register for the virtual KOL event?
Registration for the live event can be found on the TScan Therapeutics website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TCRX Insider Trading Activity
$TCRX insiders have traded $TCRX stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $TCRX stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT LP LYNX1 purchased 947 shares.
- BARBARA KLENCKE has traded it 3 times. They made 3 purchases, buying 15,000 shares and 0 sales.
- ZORAN ZDRAVESKI (See Remarks) sold 164,686 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TCRX Hedge Fund Activity
We have seen 44 institutional investors add shares of $TCRX stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CHECKPOINT CAPITAL L.P. added 825,341 shares (+inf%) to their portfolio in Q3 2024
- LMR PARTNERS LLP removed 593,729 shares (-89.2%) from their portfolio in Q3 2024
- INVESCO LTD. removed 481,858 shares (-96.4%) from their portfolio in Q3 2024
- PARADIGM BIOCAPITAL ADVISORS LP removed 353,886 shares (-100.0%) from their portfolio in Q3 2024
- NORTHERN TRUST CORP added 226,764 shares (+232.5%) to their portfolio in Q3 2024
- VANGUARD GROUP INC added 213,281 shares (+10.0%) to their portfolio in Q3 2024
- BLACKROCK, INC. added 170,524 shares (+3.8%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event to discuss data from the ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and the clinical development strategy for the heme program. Additionally, the Company will provide an update on its PLEXI-T Phase 1 solid tumor trial. The virtual event will take place on Tuesday, December 10, at 8:00 a.m. ET.
The event will provide an in-depth review of the oral presentation describing the preliminary results from TScan’s ongoing ALLOHA Phase 1 heme trial of TSC-100 and TSC-101 in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning. The Company will also provide updates with regards to a potential registrational path for the program following its initial meeting with the U.S. Food and Drug Administration (FDA), as well as future plans to expand the program.
Featured speakers include:
-
Ran Reshef, M.D., M.Sc., Director of Translational Research, Blood and Marrow Transplantation Program, Columbia University Irving Medical Center
-
Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
-
Chrystal U. Louis, M.D., Chief Medical Officer, TScan Therapeutics
-
Shrikanta Chattopadhyay, M.D., Senior Vice President, Head of Translational Medicine, TScan Therapeutics
Registration for the live event can be found here . A replay will be made available on the “ Events and Presentations ” section of the Company’s investor relations website at ir.tscan.com .
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA TM Phase 1 heme trial). The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers and is enrolling patients into its ongoing PLEXI-T Phase 1 solid tumor trial.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
[email protected]
Maghan Meyers
Argot Partners
212-600-1902
[email protected]
